Lead Product(s) : EDTA acid,Citric Acid
Therapeutic Area : Podiatry
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Kane Biotech Announces FDA 510(k) Clearance for its coactiv+™ Antimicrobial Wound Gel
Details : coactiv+ Antimicrobial Wound Gel is indicated for management of ulcers (including diabetic foot and leg ulcers and pressure ulcers), 1st and 2nd degree burns, partial & full thickness wounds, large surface area wounds and surgical incisions for adult pop...
Brand Name : coactiv+
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 25, 2023
Lead Product(s) : EDTA acid,Citric Acid
Therapeutic Area : Podiatry
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Minocycline Hydrochloride,EDTA acid,Ethanol
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Citius Pharmaceuticals
Deal Size : Not Applicable
Deal Type : Not Applicable
Citius Pharmaceuticals to Accelerate Phase 3 Mino-Lok Trial by Expanding Trial Sites Internationally
Details : Mino-Lok (minocycline) is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections (CRBSIs) and central line associated bloodstream infections (CLABSIs).
Brand Name : Mino-Lok
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 06, 2022
Lead Product(s) : Minocycline Hydrochloride,EDTA acid,Ethanol
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Citius Pharmaceuticals
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?